Cardiawave has reported the first routine clinical treatments in Europe using Valvosoft, its CE-marked non-invasive ultrasound therapy platform for severe symptomatic aortic stenosis.
The company said several Valvosoft systems have been placed into clinical use since May 2026, with deployment progressing across hospital centres in France and wider Europe. Distribution discussions are also under way across Europe, the United Kingdom, the Middle East, and India.
Valvosoft uses non-invasive ultrasound therapy to target calcified aortic valves without surgery or implantation. The device remains investigational outside Europe and is intended solely for clinical research purposes in those markets.
Cardiawave is initially targeting patients with severe symptomatic aortic stenosis who are ineligible for immediate aortic valve replacement or unwilling to undergo such procedures. The company has said clinical studies involving 100 patients across European centres support the feasibility and safety profile of the technology.
The move from clinical approval to routine use places new demands on production, field support, installation, user training, and regulated device supply. Medical technology companies often face their hardest operational test after clinical validation, when a system has to be produced and supported consistently across multiple hospitals.
Cardiawave said it is strengthening manufacturing capability with French industrial partners to meet growing demand. Therapeutic medical devices combine hardware, software, clinical workflow, operator training, quality systems, and post-market surveillance. Clinical interest has to be matched by production systems that can preserve device performance and regulatory evidence as deployment expands.
Medtech manufacturers are increasingly using modular, validated production approaches to shorten the route from concept to repeatable output, including new platforms for medical device assembly. The same pressure exists across therapeutic equipment, where consistency, documentation, and serviceability have to develop alongside clinical adoption.
CE marking is a major milestone, but commercial deployment introduces additional pressure around supplier qualification, field service, software updates, spare parts, calibration, training, and clinical user feedback. Hospitals need confidence that equipment availability, technical support, and treatment protocols can be maintained beyond early reference centres.
Cardiovascular devices are particularly demanding because they combine clinical risk, imaging, therapy delivery, software control, and patient selection. A non-invasive platform may reduce some procedural burdens compared with implanted devices, yet it still depends on precise engineering, robust operator interfaces, controlled acoustic delivery, and close integration with hospital workflows.
Manufacturing scale-up will also have to manage market variation. Systems deployed in France, Germany, the Netherlands, the UK, or the Middle East may face different service arrangements, training models, hospital procurement routes, and regulatory follow-up requirements. Building the organisation around that variation can be as important as the device design itself.
The broader medtech market is moving toward therapies that reduce invasiveness while preserving clinical effect. Cardiovascular, oncology, neurology, diagnostics, and surgical systems are all drawing on advanced sensors, imaging, robotics, ultrasound, AI-supported planning, and precise energy delivery. Those technologies raise manufacturing expectations because devices must perform consistently while becoming easier for hospitals to adopt.
Cardiawave’s European rollout gives Valvosoft a practical test beyond controlled clinical studies. The next stage will depend on production scale, hospital support, training, distribution, and quality management. For Europe’s medtech manufacturing base, it is another example of clinical innovation becoming inseparable from industrial execution.
